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Review Article 34 
Chronic Tonsillitis and Biofilms: A Brief Overview of Treatment Modalities  35 
Abstract 36 
Recurrent tonsillitis is described as when an individual suffers from several attacks of tonsillitis 37 
per year. Chronic and recurrent tonsillitis both cause repeated occurrences of inflamed tonsils 38 
which have a significant impact on a patients’ quality of life. Numerous children suffer from 39 
recurrent tonsillitis, and sore throats and these illnesses become part of their life. 40 
Antimicrobials can provide temporary relief, but in many cases, tonsillitis recurs.  Scientists 41 
working at Washington University School of Medicine in St. Louis identified the cause of such 42 
recurrent infections as microorganisms which often create biofilms and a repository of infection 43 
in the wet and warm folds of the tonsils. This review will discuss different treatment modalities, 44 
their advantages and disadvantages and new treatment options focusing on biofilms. All 45 
treatment options should be selected based on evidence and individual need.   46 
Tonsillitis   47 
Tonsillitis is an inflammation of the pharyngeal tonsils. The inflammation may affect other areas 48 
of the back of the throat, including the adenoids and the lingual tonsils. Acute tonsillitis is an 49 
infection of the tonsils triggered by one of several types of bacteria or viruses and peritonsillar 50 
abscesses can also occur. Chronic tonsillitis is a tenacious infection of the tonsils which may 51 
result in tonsil stones. Recurrent tonsillitis ensues when an individual suffers from several 52 
incidents of tonsillitis per year. Both chronic and recurrent tonsillitis involve repeated 53 
occurrences of inflamed tonsils which can impact severely on a patients’ quality of life. 1, 2 54 
Children very often suffer from tonsillitis although it is seldom observed below the age of 2 55 
years. Tonsillitis due to Streptococcus bacteria classically happens in children aged between 5-56 
15 years, while viral tonsillitis is more prevalent in younger children. 3 Multiple studies report 57 
that the average prevalence of carrier status of school children for group A Streptococcus is 58 
15.9%. 4, 5  59 
Epidemiology of Tonsillitis   60 
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Numerous children so often suffer from recurrent tonsillitis and sore throats that these 61 
illnesses become their part of life. For example, one study indicates that approximately 30% of 62 
peritonsillar abscesses require a tonsillectomy 6 and another indicates that recurrent tonsillitis 63 
is reported in 11.7% and 12.1% of Norwegian and Turkish children respectively. 7 Many of these 64 
patients are prescribed antimicrobials which typically provide temporary relief, but then the 65 
tonsillitis recurs. 8 Scientists working at Washington University School of Medicine in St. Louis 66 
identified that recurrent infections are exacerbated by the creation of biofilms in the wet and 67 
warm folds of the tonsils by microorganisms which act as a repository of infection. 9 A study 68 
utilizing an innovative imagining technique in single sections of human mucosal tissue reports 69 
the presence of biofilms in 70.8% chronic tonsillitis patients. 10 Another study revealed that 70 
biofilms were recognized on the surface epithelium of tonsils and adenoids in many of the 71 
patients who were waiting for adenotonsillectomy due to chronic tonsillitis and adenoiditis. 11 72 
Such biofilms are also observed in other otorhinolaryngology related infections such as chronic 73 
rhinosinusitis and chronic otitis media with effusion. 12, 13 74 
A Brief Overview Regarding Biofilms  75 
Biofilms are systematized communities of microorganisms embedded in a hydrated matrix of 76 
extracellular polymeric substances causing diverse of persistent infections, including dental 77 
plaque, cystic fibrosis, urinary tract infections, osteomyelitis, and ear infections. 9, 14, 15 Biofilm 78 
formations is a prehistoric prokaryotic strategy of a microorganism to exist and grow in 79 
antagonistic settings through building innovative communities through several processes. 16-19 80 
The Dutch scientist (commonly known as the Father of Microbiology) Antonie van 81 
Leeuwenhoek used his primitive but effective microscope to observed Biofilms as early as 1674 82 
and describes aggregates of animalcules scraped from human tooth surfaces. 20, 21 The English 83 
phrase ‘survival of the fittest’ arose from Darwinian evolutionary theory and describes one of 84 
the mechanisms of natural selection. 22, 23 Bacterial biofilm formations are a form of ‘survival of 85 
the fittest’ under adverse conditions including chemical or antimicrobial treatment. 24, 25 The 86 
formation of biofilms by bacteria has four potential advantages: “i. Protection from harmful 87 
conditions in the host, ii. Sequestration to a nutrient-rich area, iii. Utilization of cooperative 88 
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Biofilms normally grow as biofilms and planktonic cultures are an in vitro artifact”. 26 Microbial 89 
biofilms were identified as a major cause of many human infections, present in more than 65-90 
80% of all human bacterial infections. 14, 27-30 Thereafter biofilm pose “a serious problem for 91 
public health because of the increased resistance of biofilm-associated organisms to 92 
antimicrobial agents and the potential for these organisms to cause infections in patients with 93 
indwelling medical devices”. 31 Biofilm formations is generally considered to arise in four core 94 
stages: (1) bacterial attachment to a surface, (2) microcolony formation, (3) biofilm maturation 95 
and (4) detachment (also called dispersal) of bacteria which may then colonize new areas. 32 96 
Multiple research reported that the process of biofilm formation is categorized by five stages. 97 
33-35 (1) Microbial cells attach to surfaces reversibly. 36 (2) Microbial cells then attach to surfaces 98 
irreversibly. 37 (3) Cells adsorbed on surfaces and grow into microcolonies, their physical 99 
dimensions estimated tens or hundreds of microns in diameter. 38 (4) There microbial fraternity 100 
grows into a three-dimensional configuration and settle down into a biofilm as cells replicate 101 
and the extracellular polymeric substances (EPS) accumulates. 39 (5) Bacterial cells detach 102 
biofilm and disperse into the bulk fluid, where they act free swimming bacteria or and form 103 
new biofilms. 16, 17 Biofilm formations were depicted in Figure 1 and 2.   104 
Distinct Features of Biofilm Bacteria  105 
Bacteria found inside biofilms have distinct features different from those of free-swimming 106 
(planktonic) bacteria of the same classes and possess a very high level of resistance to 107 
commonly-used antimicrobial remedies, biocides and antiseptics, and the host immune 108 
response. 40-42 Older, mature and impenetrable biofilms are consistently more resistant to 109 
antimicrobials than younger, less dense biofilms. 42 Bacterial cells residing in the outermost 110 
parts of the biofilm are more vulnerable to the host's defenses and antimicrobials, although 111 
these microorganisms possess numerous defensive mechanisms. The biofilm is formed of 112 
various microbial communities that create a complex three-dimensional physical barrier which 113 
hinders the diffusional penetration of antimicrobials. 17, 43, 44 The exterior layer of biofilm 114 
metabolic activity alters the local pH to be more acidic and creates anoxic zones that help to 115 
degrade antimicrobials. 45-48 The biofilm also creates nutrient-depleted areas which act on 116 
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microbes to put them into a stationary or dormant phase, which may also contribute towards 117 
antibiotic resistance. 49, 50 The extracellular matrix of the biofilm secretes polymers that bind 118 
and deactivate antimicrobials, forming an antibiotic “sink”. 51 These properties of biofilms 119 
(inadequate diffusion of nutrients, restricted antimicrobial transmission and the alteration of 120 
the environment to produce a more hostile environment) combine to produce a widespread 121 
resistance and tolerance to antimicrobials. 16, 43-56 In addition, microbes entrenched in a biofilm 122 
can exist even in high concentrations of bactericidal antimicrobials although they are 123 
abundantly sensitive to those antimicrobials in culture plates under planktonic conditions. 57 124 
This complex phenomenon is known as the “recalcitrance of biofilm bacteria toward 125 
antibiotics” 58 and microorganisms found in biofilms can be up to 500-1,000 times more tolerant 126 
to antibacterial compounds than their planktonic counterparts. 59-62 Additionally, many studies 127 
reported that as soon as a biofilm is rooted and fixed, microbes develop resistance to several 128 
categories of physicochemical aggression, including UV light, heavy metals, low pH, changes in 129 
hydration or salinity, and phagocytosis. 63-67  130 
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Figure 1:  Showing Four Different Stages of Biofilm Development.  Image was download from images for copyright free biofilm. 132 
Available at    133 
https://www.google.com/search?q=copyright+free+biofilm+image&tbm=isch&tbo=u&source=univ&sa=X&ved=0ahUKEwjNsLKryb7a134 
AhULMo8KHUXIALMQsAQIMA&biw=1280&bih=615&dpr=1.5  [Accessed April 16, 2018] 135 
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 137 
Figure 2:  Showing Five Stages of Biofilm Development.  Image was download from images for copyright free biofilm. Available at    138 
https://www.google.com/search?q=copyright+free+biofilm+image&tbm=isch&tbo=u&source=univ&sa=X&ved=0ahUKEwjNsLKryb7a139 
AhULMo8KHUXIALMQsAQIMA&biw=1280&bih=615&dpr=1.5 [Accessed April 16, 2018] 140 
 141 
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Recurrent Tonsillitis and Tonsillectomy  142 
Chronic tonsillitis affecting equally both children and adults is a serious health problem 68, 69 and 143 
whilst the definition of severe recurrent tonsillitis varies, a quantity of severity is described as 144 
five or more episodes of true tonsillitis a year, symptoms for at least a year, and episodes that 145 
are disabling and prevent normal functioning. 70, 71 In one study, the lifetime prevalence of 146 
recurrent tonsillitis is described as 11.7% (95% confidence interval, 11.0%-12.3%) with a 147 
significant preponderance of females. 7 Recurrent tonsillitis is typically treated by either surgery 148 
or, when the patient does not meet tonsillectomy benchmarks or there are surgical or medical 149 
contraindications, by medical antimicrobial intervention. 72, 73  150 
Whilst tonsillectomy (surgical removal of the tonsils, with or without adenoidectomy) as a 151 
treatment modality has been practiced for over 100 years for children, much controversy exists 152 
around its value. As for example, in 1951 the British Medical Journal reported that “it is better 153 
to delay a decision than to hurry it, and above all to avoid operating on tonsils which have been 154 
recently inflamed”. 74 One study suggests that 0.6 episodes of any type of a sore throat were 155 
reported in the first year after surgery compared to medical intervention 75 and another 156 
reported that surgery could lead to life-threatening complications. A Swedish cohort study 157 
reports that among post-tonsillectomy patients 20 years later, there was a higher incidence of 158 
“chronic, immune-mediated diseases … in the operated group”, with a statistically significant 159 
relationship between post-tonsillectomy and chronic disease, with a relative risk at 9.41 and a 160 
confidence interval from 1 (1.13 < RR < 78.14). 76 However, another research study focusing on 161 
adults found that tonsillectomy promotes and improves long-term health and quality of life, 162 
thus saving health resources. 77  163 
The decision to operate should therefore be taken with care based on an individual patient’s 164 
needs and history, plus current research evidence. 74, 76, 78, 79 In making such decisions, 165 
secondary care doctors and family medicine practitioners need to collaborate because the 166 
decision whether a tonsillectomy is necessary is quite difficult and both the GP and the 167 
otolaryngologist must contribute equally. 74 The GP knows about the patient’s frequency, 168 
duration and severity of tonsillitis whereas the ENT specialist will evaluate symptoms relating to 169 
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nasal and Eustachian impediment, and will assess whether symptoms are due to tonsillitis or 170 
chronic sinusitis. 74 171 
Treatments Aimed at Disrupting Biofilms  172 
Microbial biofilm formation is responsible for the development of acute to chronic infection in 173 
several diseases including cystic fibrosis; periodontitis; infective endocarditis; persistent otitis 174 
media; chronic rhinosinusitis; chronic tonsillitis; prostatitis; chronic osteomyelitis; atopic 175 
dermatitis; onychomycosis; dental caries; infectious kidney stones; and chronic wounds.  80-83 As 176 
well, biofilms formed on the any surface, living or non-living, even on clinical devices like 177 
pacemakers, implants and catheters, and very difficult to eradicate, which accentuates the 178 
clinical consequence, such as Pseudomonal infections can embroil any part of the human body. 179 
Further, the micro-organisms adaptive capability and genetic ups and downs of within the 180 
biofilm transform them resistant to all known antimicrobial medicines. Thereafter the 181 
Pseudomonal infections become real critical to be handle by the medical doctors and threatens 182 
human life. 83, 84 By and large it is thought that 99% of the biosphere’s bacteria to live in 183 
biofilms. Thereafter, it is believed that microbial community gain an advantage living in this 184 
state. 85 Consequently, microbial biofilms significantly affecting human health by increasing 185 
morbidity, mortality, and healthcare cost. Biofilm not only adding to hospital-acquired 186 
infections (HAIs) by increasing chronicity and persistence, but colonizing in other areas of 187 
environment instigating corrosion, fouling of water pipes, and food and pharmaceutical 188 
decomposition.14, 86-88 Another study reported microbial biofilm can stick and infect all medical 189 
devices such as orthopedic prostheses and intravascular catheters and promote up to 60% of 190 
HAIs. 89 191 
Microorganisms in biofilms are distinctively more resistant to antimicrobial agents and 192 
environmental insults and are therefore very difficult to eradicate. 42, 90-94 Biofilms in general 193 
(and chronic tonsillitis specifically) can therefore lead to substantial economic costs for 194 
countries and individuals, health concerns and an evolving public health problem in both high 195 
and low resource settings.  77, 95-100 Because of this, multiple research studies have attempted to 196 
resolve the issues of both biofilms and recurrent tonsillitis. 59, 61, 101-108  197 
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The explosion of antibiotic resistance throughout the world of many microbial strains has put 198 
pressure on the research and medical communities to find an alternative strategy for the 199 
management of biofilm-mediated diseases. 61 “Perhaps new antibiotics are not the only way to 200 
combat biofilm infections if we could make ineffective older antibiotics active again.” 59 This 201 
researcher developed a 2-amino-imidazoles molecule which is capable of disrupting biofilms 202 
through making a microorganism which was previously antibiotic-resistant more vulnerable to 203 
older antimicrobials. 59, 62 Immunotherapy (using cyclic di-nucleotides) has been effective in the 204 
management of different cancers, and this molecule has also been utilized as a therapeutic 205 
strategy for biofilm-related infections. Immunoprophylaxis and immunotherapy might 206 
therefore provide new tools to combat S. epidermidis biofilm formation. 109, 110 Recently, 207 
multiple studies revealed that a 3,5-cyclic diguanylic acid (c-di-GMP) binding protein was found 208 
in biofilm communities. 111, 112 BdcA (a protein that enhances biofilm dispersal), confiscates c-di-209 
GMP and minimizes its local concentration and is partly responsible for the reduction and 210 
down-regulation of EPS of biofilms and for the up-regulation of swimming, swarming, and 211 
planktonic microbes. 111, 112 This phenomenon has been observed in Pseudomonas species and 212 
the Rhizobium mellioti biofilm communities. 111, 112 Multiple group of scientists recently 213 
reported that CdrA (an adhesin compound) which is produced by biofilms in response to high 214 
levels of c-di-GMP that binds with Psl and stabilizes biofilm structure. 38, 106, 113 Multiple 215 
research studies have identified at least three extracellular polysaccharides (Alginate, Pel and 216 
Psl) that have been important implication in structure maintenance and antibiotic resistance of 217 
biofilm. 114-123 Another study revealed that exogenous addition of D-amino acids 109 disrupted 218 
preformed biofilms by disturbing adhesive fiber interactions and was also effective in 219 
preventing biofilm formation by S. aureus and P. aeruginosa. 124-126 One-more biofilm-220 
disassembly molecule is norspermidine which has a similar dispersal mechanism to D-amino 221 
acids by targeting the exopolysaccharides. 125 The biofilm-inhibiting properties of norspermidine 222 
were detected in Staphylococcus Aureus and Escherichia coli pellicle biofilm.125 Current 223 
research therefore needs to focus on the development of norspermidine, BdcA, D-amino acids, 224 
and other polyamines as a novel antibiofilm approach and medical communities should no 225 
longer depend exclusively on antimicrobials (which are increasingly ineffective with many 226 
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pathogenic microorganisms because of resistance) and surgery to treat infectious diseases. 104, 227 
111, 112, 124, 125  228 
Other studies have identified additional ways of disrupting biofilms. Bioactive enzymes such as 229 
dispersin or Proteinase K studied in orthopedic implants made bacteria more susceptible to 230 
antibiotics and finally eradicated the biofilm by affecting polymers or proteins of the biofilm 231 
structure. 127 Several cytotoxic agents have also been found to successfully eliminate biofilms 232 
from implant surfaces, with citric acid being reported to be the most successful in eradicating 233 
biofilms on titanium surfaces. 128 Multiple research studies have identified that an electrical 234 
current successfully detaches Staphylococcus aureus and Staphylococcus epidermis biofilms 235 
from stainless steel implants. 129-131 Another study observed that biofilms of Staphylococcus 236 
epidermis on stainless steel fasteners were successfully eradicated through pulsed 237 
electromagnetic fields in combination with gentamicin. 132 A new cluster of research studies 238 
have used laser-generated shockwaves to effectively break up biofilms. 133 The technique is 239 
founded on a Q-switched, ND: YAG rhythmically laser functioning at a “rep rate of 10 Hz with 240 
1500 mJ pulses centered at 1064 nm. The laser pulses were used to create shockwave pulses in 241 
Al coated polycarbonate substrates and a resulting peak stress of greater than 50 MPa” was 242 
able to reduce 55% living microorganisms. 134 The laser technique offers another way of 243 
disrupting biofilms and is useful in the management of infected wounds, where standard 244 
treatment modalities such as topical antimicrobials or the removal of dead, damaged, or 245 
infected tissue is unsuccessful or injurious. One study found that just 4-10 seconds of the laser 246 
therapy was able to disperse biofilms from nitinol stents on 97.9% of Pseudomonas aeruginosa 247 
to single-celled planktonic microorganisms that can be more easily treated with antibiotics. 135 248 
Another found that laser-generated shockwaves therapy quickly disrupts the biofilms in 249 
infected wounds to eliminate the microorganisms and intensify the effectiveness of topical 250 
antimicrobials in the residual biofilm. Such interventions will promote patients’ quality of life by 251 
reducing healing times, morbidity, and save healthcare costs. 136 252 
N-Acetyl-Cysteine (NAC) is an antioxidant mediator which reduces the variety of microbial 253 
bacteria on biofilm emergence and evolution, 137 inhibits the manufacturing of the extracellular 254 
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polysaccharide matrix 138 and promotes the disruption of mature biofilms. 133 NAC has been 255 
found to reduce Streptococcus pneumoniae and Haemophilus influenzae adhesion to human 256 
oropharyngeal epithelial cells in laboratory experiments. 138 Chronic infections raise 257 
prostaglandin levels and NAC effectively reduces these levels and helps to disrupt the biofilms. 258 
139-142 correspondingly, aspirin-like non-steroidal anti-inflammatory drugs (NSAIDs) decrease 259 
biofilm production and completely block fungal infections. 143 NAC interacts with the sulfhydryl 260 
group of enzymes involved in EPS production or excretion, which reduces the activity of these 261 
molecules or inhibits cysteine utilization. 144 NAC therefore, decreases in-vitro biofilm formation 262 
145 and research on salicylates shows a similar negative effect on the production of biofilm. 146 A  263 
study which applied both found that therapeutic doses of acetylsalicylic acid (ASA) and NAC 264 
diminishes tonsillar mucosal biofilm formation in chronic or recurrent tonsillitis. 102 An Iraqi 265 
study found a strong correlation between the biofilm of Streptococcus pyogenes and recurrent 266 
tonsillitis and that three types of vinegar eradicated streptococcal biofilm remarkably: Date 267 
(100%), Apple (95.5%), and Grape (90.9%). 105 A later study also demonstrated the potential of 268 
vinegar in eradicating tonsillar biofilm. 101 In a laboratory experiment, whilst washing and 269 
cleaning with a soft brush did not remove the chronic tonsillitis biofilm layer on the tonsil 270 
surface in, using a harder brush removed more biofilm. 103 Researchers believe that the physical 271 
removal of biofilm (by brushing or using ultrasound-activated bubbles) from the tonsil surface 272 
in vivo will lead to greater effectiveness of topical antimicrobials and decrease the need for 273 
systemic antimicrobials. 103  274 
Conclusion 275 
Recurrent or chronic tonsillitis is currently a global public health issue which can severely impair 276 
an individuals’ quality of life. 77, 147 Microbial biofilms are a major cause of repeated tonsillitis in 277 
both pediatric and adult cohorts and more research is needed to develop new treatment 278 
strategies. 107,148, 149 Treatment modalities should however be based on careful selection and 279 
individual consideration of the potential impact of biofilms on cases of recurrent tonsillitis. 74 280 
Rather than developing or using more potent antimicrobials, doctors should ensure they are 281 
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up-to-date with research and the treatment of biofilms, including the application of topical 282 
agents, the physical removal of biofilms and other innovative treatments.  283 
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